Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Rexlemestrocel-L (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- 27 Feb 2018 According to a Mesoblast media release,this trial is being funded by the United States National Institutes of Health and the Canadian Institute of Health Research.
- 21 Dec 2017 According to a Mesoblast media release, primary endpoint will be reached in Q1 2018.
- 14 Sep 2017 Planned End Date changed from 1 Jan 2019 to 1 Aug 2019.